<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">Sinusoidal obstruction syndrome</z:e> (SOS) occurs in 50-70% of patients after <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> treatment for hepatic colorectal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>SOS is associated with <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> and is caused by oxidative damage to endothelial cells and matrix metalloproteinase (MMP) induction </plain></SENT>
<SENT sid="2" pm="."><plain>We studied the effect of a <z:chebi fb="5" ids="47916">flavonoid</z:chebi> (monoHER) on SOS prevention </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: A <z:chebi fb="0" ids="6980">monocrotaline</z:chebi> (MTC) SOS model was used in rats, with pre-treatment of monoHER </plain></SENT>
<SENT sid="4" pm="."><plain>We studied hepatocellular damage and MMP expression </plain></SENT>
<SENT sid="5" pm="."><plain>The potential inhibition of <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> cytotoxicity by monoHER was tested in vitro in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: MonoHER ameliorated the increase in portal pressure after MCT (72 hr: 7.3 ± 2.7 mmHg vs. 11.4 ± 3.0 mmHg, P = 0.016 MCT + monoHER vs. MCT, P &lt; 0.01) </plain></SENT>
<SENT sid="7" pm="."><plain>MonoHER prevented hepatocellular damage (ALT: 48 hr 42.2 ± 3.1 IU/L vs. 253.4 ± 171.7 IU/L, P = 0.034; 72 hr: 46.2 ± 4.3 IU/L vs. 311.9 ± 163.6 IU/L, MCT + monoHER vs. MCT, P &lt; 0.01) </plain></SENT>
<SENT sid="8" pm="."><plain>The liver damage score was lower in the monoHER group (72 hr: 4.8 ± 3.6 vs. 10.3 ± 0.5, MCT-monoHER vs. MCT, P &lt; 0.01) associated with less inflammatory cell infiltration </plain></SENT>
<SENT sid="9" pm="."><plain>Livers of MCT treated rats had higher expression of MMP-9 when compared to monoHER pairs at 24 hr (P = 0.016) and 72 hr (P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>MonoHER had no effect on in vitro proliferation of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells when used either alone or in combination with <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: MonoHER prevented MCT induced <z:hpo ids='HP_0001409'>portal hypertension</z:hpo> and hepatic injury in rats </plain></SENT>
</text></document>